ALQA - アリクア・バイオメディカル (Alliqua BioMedical Inc.) アリクア・バイオメディカル

 ALQAのチャート


 ALQAの企業情報

symbol ALQA
会社名 Alliqua BioMedical Inc (アリクア・バイオメディカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 Alliqua BioMedical Inc. is a regenerative technology company that commercializes regenerative medical products which assist the body in the repair or replacement of soft tissue. The Company develops and manufactures electron-beam cross-linked sheet gels. It serves manufacturers of medical devices cosmeceuticals and other commercial product applications. Its hydrogel platform technology allows manufacturing electron-beam cross-linked sheet gels with or without active ingredients. Through its platform the Company delivers prescription or over-the-counter medications ingredients for wound healing and skin care or other materials. It provides custom hydrogels to the original equipment manufacturer market. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix.   アリクア・バイオメディカルは米国のバイオ医薬品メ―カ―。創傷ケア技術の開発に重点を置いた高度な医療製品の開発に従事。主な製品には液体状創傷ケア用ドレッシング材「シルバ―シ―ル」と「ハイドレス」がある。湿潤環境を保つ「シルバ―シ―ル」は火傷治療にも効果がある。本社はペンシルベニア州。   
本社所在地 1010 Stony Hill Road Yardley PA 19067 USA
代表者氏名 David Ian Johnson David Ian Johnson
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 215-702-8550
設立年月日 35704
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 81人
url www.alliqua.com
nasdaq_url https://www.nasdaq.com/symbol/alqa
adr_tso
EBITDA EBITDA(百万ドル) -5.35100
終値(lastsale) 2.35
時価総額(marketcap) 11762243.5
時価総額 時価総額(百万ドル) 10.76120
売上高 売上高(百万ドル) 11.76600
企業価値(EV) 企業価値(EV)(百万ドル) -0.25980
当期純利益 当期純利益(百万ドル) -35.60800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Alliqua Biomedical Inc revenues increased 65% to $1.4M. Net loss before extraordinary items increased 62% to $4.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Loss on early extinguishment of debt increase from $0K to $1.7M (expense).

 ALQAのテクニカル分析


 ALQAのニュース

   Alliqua up 28% premarket on merger with Adynxx  2019/04/22 12:32:11 Seeking Alpha
Thinly traded nano cap Alliqua BioMedical (ALQA) is up 28% premarket on light volume on the heels of its agreement to execute a reverse merger with private
   Adynxx Announces Merger Agreement with Alliqua BioMedical and Provides Business and Clinical Update  2019/04/22 12:00:00 Benzinga
Adynxx announced plans to merge with Alliqua BioMedical and become a Nasdaq-listed public company in early 2019 Company announced receipt of substantial grant award from the National Institute on Drug Abuse to support the clinical development of brivoligide, a novel drug candidate intended to reduce both postoperative pain and the need for opioid-based therapies Company also announced plans to initiate two Phase 2 studies of brivoligide in postoperative pain with topline results expected in 2020 SAN FRANCISCO, April 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of pain and inflammatory diseases, today provided a business and clinical development update. Business Highlights and Recent Developments Adynxx entered into a merger agreement with Alliqua Biomedical, Inc. that will result in Adynxx becoming a Nasdaq-listed public company in early 2019. Immediately after the merger, the former Adynxx securityholders are expected to own approximately 86% of the combined company, and the existing stockholders of Alliqua are expected to own approximately 14% of the combined company.
   TEAM, SKX and CHKP among premarket losers  2019/04/18 13:11:05 Seeking Alpha
   Kitov Pharma leads healthcare gainers; TRACON Pharmaceuticals and MiMedx Group among losers  2019/04/12 15:03:29 Seeking Alpha
   Alliqua BioMedical declares $1.05 dividend  2019/04/11 20:56:06 Seeking Alpha
   Alliqua up 28% premarket on merger with Adynxx  2019/04/22 12:32:11 Seeking Alpha
Thinly traded nano cap Alliqua BioMedical (ALQA) is up 28% premarket on light volume on the heels of its agreement to execute a reverse merger with private
   Adynxx Announces Merger Agreement with Alliqua BioMedical and Provides Business and Clinical Update  2019/04/22 12:00:00 Benzinga
Adynxx announced plans to merge with Alliqua BioMedical and become a Nasdaq-listed public company in early 2019 Company announced receipt of substantial grant award from the National Institute on Drug Abuse to support the clinical development of brivoligide, a novel drug candidate intended to reduce both postoperative pain and the need for opioid-based therapies Company also announced plans to initiate two Phase 2 studies of brivoligide in postoperative pain with topline results expected in 2020 SAN FRANCISCO, April 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of pain and inflammatory diseases, today provided a business and clinical development update. Business Highlights and Recent Developments Adynxx entered into a merger agreement with Alliqua Biomedical, Inc. that will result in Adynxx becoming a Nasdaq-listed public company in early 2019. Immediately after the merger, the former Adynxx securityholders are expected to own approximately 86% of the combined company, and the existing stockholders of Alliqua are expected to own approximately 14% of the combined company.
   TEAM, SKX and CHKP among premarket losers  2019/04/18 13:11:05 Seeking Alpha
   Kitov Pharma leads healthcare gainers; TRACON Pharmaceuticals and MiMedx Group among losers  2019/04/12 15:03:29 Seeking Alpha
   Alliqua BioMedical declares $1.05 dividend  2019/04/11 20:56:06 Seeking Alpha
   Alliqua up 28% premarket on merger with Adynxx  2019/04/22 12:32:11 Seeking Alpha
Thinly traded nano cap Alliqua BioMedical (ALQA) is up 28% premarket on light volume on the heels of its agreement to execute a reverse merger with private
   Adynxx Announces Merger Agreement with Alliqua BioMedical and Provides Business and Clinical Update  2019/04/22 12:00:00 Benzinga
Adynxx announced plans to merge with Alliqua BioMedical and become a Nasdaq-listed public company in early 2019 Company announced receipt of substantial grant award from the National Institute on Drug Abuse to support the clinical development of brivoligide, a novel drug candidate intended to reduce both postoperative pain and the need for opioid-based therapies Company also announced plans to initiate two Phase 2 studies of brivoligide in postoperative pain with topline results expected in 2020 SAN FRANCISCO, April 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of pain and inflammatory diseases, today provided a business and clinical development update. Business Highlights and Recent Developments Adynxx entered into a merger agreement with Alliqua Biomedical, Inc. that will result in Adynxx becoming a Nasdaq-listed public company in early 2019. Immediately after the merger, the former Adynxx securityholders are expected to own approximately 86% of the combined company, and the existing stockholders of Alliqua are expected to own approximately 14% of the combined company.
   TEAM, SKX and CHKP among premarket losers  2019/04/18 13:11:05 Seeking Alpha
   Kitov Pharma leads healthcare gainers; TRACON Pharmaceuticals and MiMedx Group among losers  2019/04/12 15:03:29 Seeking Alpha
   Alliqua BioMedical declares $1.05 dividend  2019/04/11 20:56:06 Seeking Alpha

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 アリクア・バイオメディカル ALQA Alliqua BioMedical Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)